Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine.
from Medical Xpress - latest medical and health news stories https://ift.tt/Ja5yZe9
